Skip to main content

Table 1 Number of patients, PET–CTs and indication for PET–CTs according to sarcoma subtype

From: Retrospective audit of 957 consecutive 18F-FDG PET–CT scans compared to CT and MRI in 493 patients with different histological subtypes of bone and soft tissue sarcoma

Sarcoma pathological diagnosis Number of patients Number of PET–CT scans
Total Staginga (with metastasis) Restaging Treatment response
Undifferentiated pleomorphicb 81 166 64 (6) 62 40
Angiosarcomac 8 11 7 (1) 3 1
Leiomyosarcoma 89 166 43 (8) 84 39
Rhabdomyosarcoma 16 53 13 (4) 15 25
Myxofibrosarcoma 21 30 14 (2) 8 8
Epithelioid sarcoma 10 23 7 (1) 15 1
Osteosarcoma 48 98 39 (7) 28 31
Clear cell sarcoma 6 8 5 (1) 3 0
Ewing sarcoma/DSRCT 31 120 20 (6) 47 53
Synovial sarcoma 26 44 17 (3) 24 3
De-differentiated liposarcoma 18 36 11 (1) 17 8
Solitary fibrous tumour 14 25 8 (1) 9 8
Chondrosarcoma grade 2/3 24 45 18 (1) 17 10
Myxoid/round cell liposarcoma 26 36 18 (4) 12 6
Alveolar soft part sarcoma 4 4 4 (1) 0 0
MPNST 37 65 33 (4) 21 11
Low grade soft tissue sarcoma 25 17 17 (0) 0 0
Chondrosarcoma grade 1 9 10 6 (0) 4 0
Total 493 957 344 (51) 369 244
  1. DSRCT desmoplastic small round cell sarcoma, MPNST malignant peripheral nerve sheath tumour, includes low-grade
  2. aNote this is overall detection of metastatic disease at initial CT and MRI staging only, ‘added value’ comparison is reported in Table 3
  3. bIncludes high grade ‘spindle cell sarcoma’
  4. cIncludes ‘high grade epitheloid haemangioendothelioma’